Reducing Uncertainty
in the Care and Treatment of Blood Cancer
Reducing Uncertainty
in the Care and Treatment of Blood Cancer
Reducing Uncertainty
in the Care and Treatment of Blood Cancer
introducing:
FUSIONMRD™
For patients with gene fusion-driven leukemia, FusionMRD™ is a personalized digital PCR assay designed for individualized monitoring of treatment response and long-term disease surveillance.
Test more accurately. More often.
FusionMRD™ is available as a commercial service, delivering highly sensitive and specific detection and quantification of oncogenic fusions—using only a standard peripheral blood sample. Our proprietary process enables precise MRD assessment to help you make more informed clinical decisions.
Rapid Turnaround
Our streamlined sample processing and rapid analysis allow for fast, reliable results, helping you act quickly and confidently.
Exceptional Accuracy
Using ddPCR, we provide absolute oncogenic fusion quantification – down to 1 in 100,000 fusion transcripts – while maintaining an exceptionally low false-positive rate.
Low Cost
Our ddPCR-based assay eliminates the complex and expensive workflows associated with sequencing and flow cytometry, reducing costs while increasing accessibility.
Patent-pending Personalization
Personalized MRD testing targets each unique disease-defining gene fusion to ensure accurate monitoring of their disease.
Driven by expertise and innovatioN
Led by a team of dedicated oncologists and genomics specialists, we are committed to transforming blood cancer detection and enhancing patient care through sensitive, personalized MRD testing.
Driven by expertise and innovatioN
Led by a team of dedicated oncologists and genomics specialists, we are committed to transforming blood cancer detection and enhancing patient care through sensitive, personalized MRD testing.
Driven by expertise and innovatioN
Led by a team of dedicated oncologists and genomics specialists, we are committed to transforming blood cancer detection and enhancing patient care through sensitive, personalized MRD testing.
Our sensitive assays allow researchers to gauge therapeutic success long before traditional endpoints, shortening trial timelines and increasing confidence in new therapies.
Andrew Young, MD, PhD, Founder & CSO Pairidex
Our sensitive assays allow researchers to gauge therapeutic success long before traditional endpoints, shortening trial timelines and increasing confidence in new therapies.
Andrew Young, MD, PhD
Founder & CSO Pairidex
Connect with us
Discover how our innovative solutions can transform your approach to cancer detection and monitoring. We’d love to show you what we can do.